Secondary myelodysplasia of donor cell origin following nonmyeloablative sibling allogeneic stem cell transplantation [8]

Bone Marrow Transplantation

Volumn 36, Issue 5, 2005, Pages 471-472

  Boulton Jones, R ^a   Parker, A ^b   Hepburn, M ^a   Bowen, D T ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CD3 ANTIGEN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ALOPECIA AREATA; CANCER RELAPSE; CASE REPORT; CYTOPENIA; FOLLICULAR LYMPHOMA; HUMAN; LETTER; LOW DRUG DOSE; MALE; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; ORGAN DONOR; PRIORITY JOURNAL; SIBLING; SPLENECTOMY;

HUMANS; LIVING DONORS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; SIBLINGS; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 30944441884     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705086     Document Type: Letter

References (2)

1. Faulkner RD, Craddock C, Byrne JL et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 2004; 103: 428-434.
2. McCann S, Wright E. Donor leukaemia: Perhaps a more common occurrence than we thought!. Bone Marrow Transplant 2003; 32: 455-457.